
Facial sweating treatment is not limited to an application intended only to stop sweating temporarily. First, it must be determined whether the sweating is a normal physiological response, primary craniofacial hyperhidrosis, or secondary sweating caused by another health condition.
Sweating of the face during hot weather, exercise, stress, or the consumption of spicy foods may be considered natural. However, treatment planning may be necessary if sweating occurs in a cool environment, without physical activity, or at a severity that affects daily life.
There is no single treatment method applied to everyone with facial sweating. Treatment is planned individually by considering the cause and severity of sweating, the areas of the face affected, whether other parts of the body are involved, the medications used by the patient, and the methods previously tried.
In some patients, controlling triggers and using topical products may be sufficient. In others, oral medications or botulinum toxin injections may be considered. In primary facial sweating that seriously affects quality of life despite other treatments, surgical treatment may be discussed after appropriate patient selection.
The first stage of treatment planning is a detailed evaluation of the characteristics of sweating. Simply stating, “My face sweats excessively,” is not enough to determine the treatment method.
During the evaluation, answers to the following questions are investigated:
This assessment provides clearer information about the type and severity of sweating.
One of the most important steps in planning facial sweating treatment correctly is distinguishing between primary and secondary hyperhidrosis.
In primary craniofacial hyperhidrosis, there is no identifiable disease causing the excessive sweating. The number of sweat glands is usually normal. The problem is that the sympathetic nervous system, which controls the sweat glands, is overactive.
In primary facial sweating, symptoms usually:
The patient’s medical history and physical examination play an important role in diagnosing primary hyperhidrosis.
In secondary hyperhidrosis, sweating develops because of another health condition, hormonal change, or medication.
Conditions that may be associated with secondary sweating include:
In secondary sweating, the priority is to identify and, if possible, treat the underlying cause before directly suppressing the sweating.
The treatment method is not determined solely by the amount of sweat. The effect of sweating on the person’s life is also assessed.
In some patients, sweating may be noticeable but may not seriously interfere with daily life. In others, a similar amount of sweating may significantly complicate job interviews, meetings, social relationships, or everyday communication.
Situations that may indicate that facial sweating is affecting quality of life include:
When treatment success is assessed, attention is given not only to whether sweating has stopped completely but also to whether the person feels more comfortable in daily life.
In primary facial sweating, treatment is generally planned gradually, beginning with less invasive methods. However, this order may not be the same for every patient.
The severity of sweating, skin structure, previously applied treatments, and the patient’s expectations may change the order of treatment.
The first step usually includes identifying triggers, making lifestyle adjustments, and considering topical treatments in appropriate patients.
Controlling triggers may not eliminate hyperhidrosis completely. However, it may reduce the frequency or severity of sweating episodes.
Common triggers that may increase facial sweating include:
Recording the situations in which sweating increases may help identify personal triggers.
Reducing stress, choosing cooler environments, and limiting food-related triggers may support treatment. However, primary hyperhidrosis is not caused only by anxiety or poor eating habits. Therefore, advising the patient merely to “avoid stress” or “think less” is not an adequate treatment approach.
Topical treatments are products applied directly to the sweating area. Some antiperspirant products may temporarily affect the sweat gland ducts and reduce the amount of sweat reaching the skin surface.
Antiperspirants containing aluminium salts may be among the first treatment options for some forms of hyperhidrosis. However, facial skin is more sensitive than the skin of the underarms, hands, or feet.
Using the wrong product or an unsuitable concentration on the face may cause:
For this reason, the content, frequency of application, and treatment area of products used on the face should be determined by a doctor. These products should not come into contact with the eye area, damaged skin, or mucous membranes.
Topical treatments with anticholinergic properties may also be considered in some patients. However, their use on the face may vary according to the country, the licensing status of the product, and the patient’s characteristics. They should not be used without supervision because contact with the eyes may cause pupil dilation, blurred vision, or other side effects.
Certain oral medications may be considered in patients whose topical treatments are insufficient, whose sweating affects several areas, or whose symptoms are pronounced.
Anticholinergic medications may reduce the effect of nerve signals stimulating the sweat glands. Medications such as oxybutynin or glycopyrrolate may be used in some patients with hyperhidrosis. However, these medications are not suitable for every patient, and the conditions under which they are used for hyperhidrosis may vary by country.
Possible side effects include:
Suppressing sweating may also affect the body’s ability to regulate temperature. Therefore, treatment should be planned carefully in people who work in hot environments, perform intense exercise, or are exposed to conditions that increase body temperature.
Medication selection is also evaluated carefully in older adults and in people with glaucoma, prostate enlargement, difficulty urinating, or certain heart conditions.
The dose, duration of use, and whether treatment should continue must be determined by a doctor.
In some people, facial sweating increases especially during job interviews, presentations, examinations, stage performances, or public speaking.
In these patients, treatment may be planned for specific situations rather than as a continuously used medication. After medical evaluation, certain medications intended to reduce the physical signs of stress may be considered in suitable patients.
Because these medications may affect heart rate and blood pressure, they cannot be used by everyone. Self-medication may be unsafe in people with asthma, low blood pressure, heart rhythm disorders, or another chronic condition.
Psychological support, breathing exercises, or anxiety management methods may also be added to the treatment plan for sweating that increases with stress. However, these approaches do not eliminate the physiological aspect of primary hyperhidrosis. The aim of treatment is to manage both nervous system-related sweating and the anxiety cycle created by sweating.
Botulinum toxin temporarily reduces the chemical signals transmitted from nerve endings to the sweat glands. This may decrease sweat production in the treated area.
Botulinum toxin treatment for facial and scalp sweating may be considered particularly in patients who:
Before the procedure, the areas where sweating is most intense are identified. Botulinum toxin is injected into the skin in small doses using fine needles.
Its effect usually begins during the days following treatment. The result is not permanent. Sweating may return as the effect wears off, and the procedure may need to be repeated in appropriate patients.
Facial muscles are involved in speaking, smiling, raising the eyebrows, and other facial expressions. Therefore, injection points and doses must be planned carefully when botulinum toxin is used for facial sweating.
Possible side effects, depending on the treatment area, include:
The risk profile of scalp injections may differ from injections given to areas of the forehead and face where facial expression muscles are located. The treatment area is determined according to the distribution of sweating.
It is important for botulinum toxin treatment to be performed by a physician experienced in hyperhidrosis and facial anatomy.
Iontophoresis is a hyperhidrosis treatment in which a low-intensity electrical current is transmitted to the skin through water. It is one of the methods commonly used for hand and foot sweating.
Although some special devices have been developed for facial use, the face requires caution because of the eyes, nerves, and sensitive skin structure. Iontophoresis is not as standard or widely used for facial sweating as it is for hand and foot sweating.
If this method is considered, the device must be suitable for facial use, the eyes must be protected, and the procedure should be performed according to the recommendations of a healthcare professional.
Iontophoresis may not be suitable during pregnancy, in people with pacemakers or certain electronic implants, or in the presence of some metal implants.
A single treatment method may not be sufficient in some patients. In this case, different methods may be used together or alternately.
For example:
In a combined treatment plan, medication side effects, the frequency of repeat procedures, and the patient’s adherence to treatment are evaluated together.
Surgical treatment is not the first option for every patient with facial sweating. It must first be confirmed that the sweating is caused by primary craniofacial hyperhidrosis.
Surgical treatment may be considered in the following situations:
If there are night sweats, generalised sweating affecting the whole body, or sweating that began suddenly and recently, the underlying cause should be investigated first. Sympathetic surgery is not planned directly in such situations.
Some of the sympathetic nerve pathways controlling facial sweating pass through the chest cavity. During endoscopic thoracic sympathetic surgery, the chest cavity is entered through small incisions, and the relevant sympathetic nerve pathways are interrupted or modified.
Depending on the method used, the procedure may be described by different terms, including:
These procedures are not identical. The level of the nerve treated and the technique used may vary according to the affected area and the surgeon’s assessment.
Because facial sweating may require intervention at higher levels of the sympathetic nervous system, the procedure may be planned differently from surgery performed for hand or underarm sweating.
The operation is performed under general anaesthesia. During surgical planning, the patient’s age, general health, lungs, previous chest operations, and distribution of sweating are assessed.
Ramicotomy is one of the surgical approaches intended to treat selected connecting branches leading from the sympathetic nerve to the sweat glands rather than completely cutting the main sympathetic trunk.
The aim of this approach is to reduce nerve transmission related to sweating while preserving as much of the sympathetic system as possible. However, nerve anatomy and patient response may vary from person to person.
Whether ramicotomy is suitable for surgical planning depends on:
No surgical method can be said to eliminate the risk of compensatory sweating completely. Therefore, the advantages and limitations of the method should be explained realistically before surgery.
Endoscopic thoracic sympathetic surgery may provide a significant reduction in facial sweating. However, the possible risks and long-term outcomes of the operation should be evaluated before the procedure.
One of the most important issues is compensatory sweating. Increased sweating in other areas of the body after surgery is known as compensatory sweating.
Increased sweating may occur in areas such as:
The severity of compensatory sweating varies from person to person. In some people it is mild and tolerable, while in others it may affect daily life.
Other possible risks include:
The likelihood of these risks varies according to the technique used, the level treated, the surgeon’s experience, and the patient’s characteristics.
A rapid and significant reduction in facial sweating may occur after surgical treatment. However, it cannot be guaranteed that every patient will have the same result or that sweating will disappear from the entire body.
The purpose of surgery is not to stop the body’s natural sweating mechanism completely. The aim is to reduce uncontrollable excessive sweating in the facial area and improve the patient’s quality of life.
When surgical success is assessed, the following are considered together:
The decision for surgery should not be based only on the desire to eliminate facial sweating. The patient must understand that sweating may increase in other areas and that the procedure may create permanent changes in the nervous system.
The duration of treatment varies depending on the method used.
Controlling triggers and using topical treatments may require regular application. Oral medications may be used for certain periods depending on benefit and side effects.
The effect of botulinum toxin is temporary. When the effect decreases, the procedure may be repeated in appropriate patients.
Surgical treatment aims to create a permanent change in the sympathetic nerve pathways. However, follow-up continues after surgery to evaluate changes in sweating distribution and possible side effects.
Failure to see results during the first days does not always mean that the treatment has failed. Some treatments require a certain period before their effect can be assessed.
Successful treatment does not mean only that the face remains completely dry. Excessive dryness may also cause discomfort.
The following changes are assessed after treatment:
If the method used is not sufficient, the dose, duration, or treatment method may be reassessed. Some patients may be switched to a different treatment, or more than one method may be used together.
The cause and effect of facial sweating differ in every patient. Therefore, the treatment plan should be personalised.
The treatment of a person who sweats only on the forehead may not be the same as that of someone who has sweating of the face, scalp, hands, and underarms.
Similarly, the needs of a person who sweats only during presentations are different from those of someone who experiences uncontrollable sweating throughout the day.
The following factors are considered together when selecting treatment:
The aim is to provide meaningful relief in daily life with the lowest possible risk.
Facial sweating treatment begins with determining the cause and severity of the sweating. Primary craniofacial hyperhidrosis must be distinguished from secondary sweating caused by another disease or medication.
In secondary sweating, the priority is to treat the underlying cause. In primary facial sweating, treatment may be planned gradually, beginning with less invasive methods.
Controlling triggers, topical treatments, oral medications, and botulinum toxin injections are among the non-surgical options. Surgical methods may be considered in severe primary facial sweating that significantly affects quality of life and does not respond to other treatments.
When deciding on endoscopic thoracic sympathetic surgery or ramicotomy, compensatory sweating and other surgical risks should be considered alongside the expected benefits.
The most appropriate treatment is determined by evaluating the location of sweating, the patient’s complaints, previously applied methods, and treatment expectations together.
Facial sweating may be controlled or significantly reduced with different methods. The duration of the result varies according to the treatment applied. Topical products, medications, and botulinum toxin may provide temporary effects. Surgical methods may offer more permanent results but carry different risks.
The first treatment varies according to the cause and severity of sweating. In mild primary facial sweating, controlling triggers and using topical products recommended by a doctor may be considered. In severe or widespread sweating, other methods may be introduced earlier.
Some antiperspirants may be used for facial sweating. However, because facial skin is sensitive, product selection and application frequency must be determined carefully. The product should not be applied around the eyes, and high-concentration products should not be used without medical advice.
Certain medications with anticholinergic properties may reduce sweating. However, side effects such as dry mouth, constipation, blurred vision, and increased sensitivity to hot weather may occur. Medication treatment should be planned according to the patient’s general health.
The effect of botulinum toxin is temporary, and its duration varies from person to person. Sweating may return when the effect wears off. The procedure may be repeated at certain intervals in appropriate patients.
When botulinum toxin is injected near facial muscles, it may cause temporary changes in facial expressions. This risk is reduced by carefully planning the treatment area and dose.
In facial sweating that increases with stress, trigger management, psychological support, and medication treatment may be considered together in appropriate patients. However, long-standing primary hyperhidrosis should not be regarded only as a psychological problem.
Surgical treatment may be considered in selected patients with primary facial hyperhidrosis whose sweating seriously affects quality of life and who do not obtain sufficient benefit from appropriate non-surgical treatments.
Sweating may increase in areas such as the back, chest, abdomen, waist, or legs after surgery. The severity of this condition, known as compensatory sweating, varies from person to person. This risk should be evaluated in detail before surgery.
The initial evaluation may be performed by dermatology, internal medicine, or family medicine. Depending on the underlying cause, assessment by endocrinology or neurology may be necessary. Patients diagnosed with primary hyperhidrosis who are considering surgical treatment are evaluated by a thoracic surgeon.